High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.

Joan FrigolaCaterina CarbonellPatricia IraznoNuria PardoAna CallejoSusana CedresAlex Martinez-MartiAlejandro NavarroMireia SoledaJose JimenezJavier Hernandez-LosaAna VivancosEnriqueta FelipRamon Amat

Published in: Journal for immunotherapy of cancer (2022)

SCNAs burden is a potential biomarker of benefit to ICIs in patients with NSCLC, although there appear to be some nuances worth consideration. Further studies will be needed to establish its role as a biomarker of benefit to ICIs.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
copy number
dna damage
cell cycle
brain metastases
dna methylation
case control